| __timestamp | Taro Pharmaceutical Industries Ltd. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 91733000 | 59644696 |
| Thursday, January 1, 2015 | 87644000 | 79541000 |
| Friday, January 1, 2016 | 92365000 | 98015000 |
| Sunday, January 1, 2017 | 85656000 | 103958000 |
| Monday, January 1, 2018 | 88196000 | 103654000 |
| Tuesday, January 1, 2019 | 89971000 | 128951000 |
| Wednesday, January 1, 2020 | 93413000 | 135799000 |
| Friday, January 1, 2021 | 91355000 | 149883000 |
| Saturday, January 1, 2022 | 113676000 | 220206000 |
| Sunday, January 1, 2023 | 198366000 | 265542000 |
| Monday, January 1, 2024 | 218935000 |
Unveiling the hidden dimensions of data
In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Taro Pharmaceutical Industries Ltd. and Travere Therapeutics, Inc. have shown contrasting trends in their SG&A cost management from 2014 to 2023.
Taro has maintained a relatively stable SG&A expense, with a notable increase of approximately 138% from 2014 to 2023. In contrast, Travere's SG&A expenses surged by around 345% over the same period, indicating a more aggressive expansion strategy.
While Taro's expenses peaked in 2024, Travere's data for 2024 is missing, leaving room for speculation. This comparison highlights the strategic differences in cost management between the two companies, offering valuable insights for investors and industry analysts.
Understanding these trends can provide a competitive edge in making informed investment decisions.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.